The debate over which form of stem cells will be most beneficial for clinical applications is far from over, and there may well never be a clear “winner.” The true winners will be the patients who will benefit from whichever method proves most feasible, cost effective, broadly accessible, and acceptable to regulatory agencies—whatever cell-based therapies can deliver the cures needed regardless of the source of the cells.

0

Submit a comment

Your email address will not be published. Required fields are marked *

There are 0 comments